Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease

Charité University Medicine Berlin

Status: Completed

Conditions: Aging; Chronic Kidney Diseases; Microbial Colonization; Cardiovascular Diseases

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04976010

EA2/162/17

Details and patient eligibility

About

Chronic kidney disease (CKD) is associated with an increased cardiovascular mortality. In particular children with early-onset CKD have a lifelong increased risk to suffer from cardiovascular disease (CVD). Therefore, children with CKD deserve our attention. The immune system in children with CKD is disturbed, exhibiting pro-inflammatory features. Therefore, we aim to learn more about the characteristics of the immune system in early-onset CKD. In this project PBMC of pediatric CKD patients and age-matched healthy controls will be analysed and compared using CITE-Seq as a multimodal scRNAseq phenotyping method. All patients will be clinically characterized to integrate cardiovascular and immunological data.

Enrollment: 38 patients

Sex: All

Ages: 5 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• matching to one of the following groups CKD G3-5: estimated eGFR according to Schwartz formula <60ml/min*1,73m2 (no ESKD) CKD G5 D: patients with ESKD treated with hemodialysis for at least 3 months normal kidney function: CKD G1 or no CKD with eGFR > 90ml/min*1,73m2
• informed consent to participate in this study

Exclusion criteria

• body weight of less than 15kg
• acute or chronic inflammatory diseases
• fever
• diabetes
• chronic liver disease
• inflammatory bowel disease or other gastrointestinal disorders (constipation, diarrhea, short bowel syndrome)
• antibiotic prophylaxis or treatment within four weeks prior to recruitment

Trial design

38 participants in 3 patient groups

CKD G3-5

Description:

Patients with CKD and an estimated eGFR \< 60ml/min not yet on dialysis

Treatment:

Other: No intervention

End stage kidney disease (ESKD) CKD G5 Hemodialysis

Description:

Patients on hemodialysis for at least 3 months

Treatment:

Other: No intervention

Normal kidney function

Description:

Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR \> 90ml/min

Treatment:

Other: No intervention